Iain Stuart
Chief Tech/Sci/R&D Officer chez VYNE THERAPEUTICS INC.
Fortune : 298 593 $ au 29/02/2024
Profil
Currently, Iain A.
Stuart is Chief Scientific Officer for VYNE Therapeutics, Inc.
Dr. Stuart previously was Project Manager-Pharmaceutical Development at Cyclacel Pharmaceuticals, Inc., Chief Research & Development Officer at VYNE Pharmaceuticals Ltd., Chief Scientific Officer for Menlo Therapeutics, Inc., Senior Director-Study at Inveresk Research Group, Inc. and VP-Medical Strategy & Scientific Affairs at Leo Pharma, Inc.
Iain A.
Stuart received a doctorate and an undergraduate degree from Glasgow Caledonian University.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
VYNE THERAPEUTICS INC
0,96% | 02/01/2024 | 133 898 ( 0,96% ) | 298 593 $ | 29/02/2024 |
Postes actifs de Iain Stuart
Sociétés | Poste | Début |
---|---|---|
VYNE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | 01/03/2020 |
Anciens postes connus de Iain Stuart
Sociétés | Poste | Fin |
---|---|---|
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Chief Tech/Sci/R&D Officer | 09/03/2020 |
Leo Pharma, Inc.
Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Corporate Officer/Principal | 01/01/2016 |
VYNE THERAPEUTICS INC. | Chief Tech/Sci/R&D Officer | - |
CYCLACEL PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Inveresk Research Group, Inc.
Inveresk Research Group, Inc. Miscellaneous Commercial ServicesCommercial Services Inveresk Research Group, Inc. provides drug development services to companies in the pharmaceutical and biotechnology industries. The company offers pre-clinical safety & pharmacology evaluation, laboratory sciences, and clinical development services. Inveresk Research Group was founded in 1999 and is headquartered in Cary, NC. | Corporate Officer/Principal | - |
Formation de Iain Stuart
Glasgow Caledonian University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
CYCLACEL PHARMACEUTICALS, INC. | Health Technology |
VYNE THERAPEUTICS INC. | Health Technology |
Entreprise privées | 4 |
---|---|
Inveresk Research Group, Inc.
Inveresk Research Group, Inc. Miscellaneous Commercial ServicesCommercial Services Inveresk Research Group, Inc. provides drug development services to companies in the pharmaceutical and biotechnology industries. The company offers pre-clinical safety & pharmacology evaluation, laboratory sciences, and clinical development services. Inveresk Research Group was founded in 1999 and is headquartered in Cary, NC. | Commercial Services |
VYNE Pharmaceuticals Ltd.
VYNE Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology VYNE Pharmaceuticals Ltd. operates as a pharmaceutical company, which focuses on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Its product portfolios include minocycline foam, minocycline gel, mometasone foam, calcipotriene foam, triamcinolone acetonide foam, betamethasone valerate foam, and betamethasone dipropionate. The company was founded by Dov Tamarkin and Meir Eini on January 19, 2003 and is headquartered in Rehovot, Israel. | Health Technology |
Menlo Therapeutics, Inc.
Menlo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Menlo Therapeutics Inc. operates as biopharmaceutical company which is focused on the development and commercialization of serlopitant for the treatment of pruritus, or itch, associated with dermatologic conditions such as atopic dermatitis, psoriasis and prurigo nodularis. The company was founded by Ed F. Schnipper in October, 2011 and is headquartered in Bridgewater, CA. | Health Technology |
Leo Pharma, Inc.
Leo Pharma, Inc. Drugstore ChainsRetail Trade Leo Pharma, Inc. is engaged in the development, manufacture, and marketing of pharmaceutical drugs. Its products are used for dermatologic and thrombotic patients. The company was founded in 1908 and is headquartered in Parsippany, NJ. | Retail Trade |